Furthermore, we observed that Ad-hNIS infection of cancer cells induced increased uptake of I-125 and Tc-99m pertechnetate in infected human colon cancer cells inin vitroandin vivomodels (Figures 1aand4). shRNA and hNIS radioiodine gene therapy using an adenoviral vector system in a mouse colon cancer model. Adenovirus-mediated cancer gene therapy using MDR1 shRNA and hNIS would be a useful tool for the treatment of cancer cells expressing multi-drug resistant genes. Keywords:MDR1, shRNA, hNIS, Radioiodine gene therapy, imaging == Introduction == The human sodium/iodide symporter (NIS) protein is an active iodide transporter.1As the transfer of theNISgene and the subsequent functional expression of NIS protein induce cancer cells to Nodakenin accumulate therapeutic radionuclides (I-131 and Re-188) from plasma,NISgene transfer represents a possible type of radionuclide gene therapy. Several investigators have reported that human sodium/iodide symporter (hNIS) mediated radionuclide gene therapy would offer a potential means of cancer therapy.2,3,4,5,6 Multidrug resistance (MDR) is the most common impediment to successful chemotherapy for various cancers. Classic MDR is characterized by Rabbit polyclonal to Fyn.Fyn a tyrosine kinase of the Src family.Implicated in the control of cell growth.Plays a role in the regulation of intracellular calcium levels.Required in brain development and mature brain function with important roles in the regulation of axon growth, axon guidance, and neurite extension.Blocks axon outgrowth and attraction induced by NTN1 by phosphorylating its receptor DDC.Associates with the p85 subunit of phosphatidylinositol 3-kinase and interacts with the fyn-binding protein.Three alternatively spliced isoforms have been described.Isoform 2 shows a greater ability to mobilize cytoplasmic calcium than isoform 1.Induced expression aids in cellular transformation and xenograft metastasis. cross resistance to antineoplastic drugs and is caused by overexpression of theMDR1gene that encodes P-glycoprotein (Pgp), a member of the ATP-binding cassette transporter superfamily.7Most efforts to reverse MDR during the past decades have Nodakenin focused on the use of compounds that modulate Pgp activity. However, the efficiency of these drugs was difficult to Nodakenin assess because of inherent adverse side effects such as hypotension and heart failure. Moreover, tumor cells can acquire resistance to the applied chemosensitizer’s so-called tertiary resistance. Experimental therapeutic strategies to reverse MDR are under investigation. These strategies included gene therapeutic approaches with the use of antisense oligonucleotides, ribozymes or DNAzymes and, most recently, the application of RNA interference (RNAi) technology.8,9RNAi is a conserved cellular mechanism where double-stranded RNA silences the corresponding homologous gene.8,9Double-stranded small-interfering RNA (siRNA) molecules with a length of 1925 nucleotides can direct degradation of eukaryotic mRNAs in a sequence-specific manner. Transient RNAi can be attained by application of siRNAs, whereas stable RNAi-mediated gene silencing can be achieved by transfection of mammalian cells with short hairpin RNA (shRNA) encoding expression cassettes that are localized on plasmid or viral vectors. Previously, we have reported on Nodakenin the increased therapeutic effects of combination MDR1, shRNA and hNIS radioiodine gene therapy in human cancer cellsin vitrousing stable transfectants that express MDR1 shRNA for theMDR1gene and humanNIS(hNIS) gene.10Although thein vitrostudy showed a therapeutic effect in a human colon cancer model, the application of our findings Nodakenin in a clinical setting is not straightforward. We have attempted to identity a new method to treat drug-resistance cancer effectivelyin vivo, which mimics the clinical situation. Among various therapeutic strategies, we have focused on the use of adenovirus-mediated therapeutic gene delivery in anin vivocancer model. An adenoviral vector is the major delivery system commonly used for gene therapyin vivo.11,12The use of an adenoviral vector system has been reported to have several beneficial features as compared with other viral vector systems, such as efficient transfection in various cells including both quiescent and dividing cells, and high level expression of the gene of interest by the use of a cytomegalovirus promoter during the short term. In this study, we have attempted to show whether adenovirus-mediated MDR1 shRNA plus hNIS gene transfer in a human colon cancer model would be potentially visualized by the use of nuclear imaging and subsequently generate strong therapeutic effectsin vivo. == Materials and methods == == Cells and animals == The human colon cancer cell line HCT-15 was maintained in RPMI 1640 containing 20% fetal bovine serum (Hyclone, Logan, UT) and 50 units ml1streptomycin/penicillin (GibcoBRL, Grand.